Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.

Gemcitabine is a first-line agent for advanced pancreatic cancer therapy. However, its efficacy is often limited by its poor intracellular metabolism and chemoresistance. To exert its antitumor activity, gemcitabine requires to be converted to its active triphosphate form. Thus, our aim was to improve gemcitabine activation using gene-directed enzyme prodrug therapy based on gemcitabine association with the deoxycytidine kinase::uridine monophosphate kinase fusion gene (dCK::UMK) and small interference RNA directed against ribonucleotide reductase (RRM2) and thymidylate synthase (TS). In vitro, cytotoxicity was assessed by 3-[4,5-dimethylthiazol-2-yl]-3,5-diphenyl tetrazolium bromide and [(3)H]thymidine assays. Apoptosis-related gene expression and activity were analyzed by reverse transcription-polymerase chain reaction, Western blot, and ELISA. For in vivo studies, the treatment efficacy was evaluated on subcutaneous and orthotopic pancreatic tumor models. Our data indicated that cell exposure to gemcitabine induced a down-regulation of dCK expression and up-regulation of TS and RR expression in Panc1-resistant cells when compared with BxPc3- and HA-hpc2-sensitive cells. The combination of TS/RRM2 small interference RNA with Ad-dCK::UMK induced a 40-fold decrease of gemcitabine IC(50) in Panc1 cells. This strong sensitization was associated to apoptosis induction with a remarkable increase in TRAIL expression and a diminution of gemcitabine-induced nuclear factor-kappaB activity. In vivo, the gemcitabine-based tritherapy strongly reduced tumor volumes and significantly prolonged mice survival. Moreover, we observed an obvious increase of apoptosis and decrease of cell proliferation in tumors receiving the tritherapy regimens. Together, these findings suggest that simultaneous TS/RRM2-gene silencing and dCK::UMK gene overexpression markedly improved gemcitabine's therapeutic activity. Clearly, this combined strategy warrants further investigation.

[1]  U. Fink,et al.  Chemotherapy in advanced pancreatic adenocarcinoma. , 1998, Cancer treatment reviews.

[2]  Benjamin Rs.  Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. , 1995 .

[3]  A. Arlt,et al.  NFkappaB-dependent chemoresistance in solid tumors. , 2002, International journal of clinical pharmacology and therapeutics.

[4]  F. Bucchieri,et al.  Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell lung cancer (NSCLC) cell lines , 2000, Cancer Chemotherapy and Pharmacology.

[5]  A. Karlsson,et al.  Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. , 2000, Pharmacology & therapeutics.

[6]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Burris,et al.  Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. , 1997, European journal of cancer.

[8]  J. Mackey,et al.  Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene , 2004, BMC pharmacology.

[9]  J. Mackey,et al.  Nucleoside analogues and nucleobases in cancer treatment. , 2002, The Lancet. Oncology.

[10]  I. Talianidis,et al.  Activation of deoxycytidine kinase by inhibition of DNA synthesis in human lymphocytes. , 2001, Biochemical pharmacology.

[11]  S. Ménard,et al.  Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. , 2005, Cancer research.

[12]  M. Xiong,et al.  Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  D. Martin,et al.  Ribonucleotide reductase in cultured mouse lymphoma cells. Cell cycle-dependent variation in the activity of subunit protein M2. , 1981, The Journal of biological chemistry.

[14]  D. V. Von Hoff,et al.  A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  H. Friess,et al.  Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells. , 2006, Anticancer research.

[16]  G. Peters,et al.  Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. , 2000, European journal of cancer.

[17]  C. R. Crawford,et al.  Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. , 1998, Cancer research.

[18]  R. Abrams,et al.  Pancreatic cancer. , 2002, Current problems in cancer.

[19]  P. Vandenabeele,et al.  Gap junctions and the propagation of cell survival and cell death signals , 2005, Apoptosis.

[20]  P. Dent,et al.  Kinase Inhibitors and Cytotoxic Drug Resistance , 2004, Clinical Cancer Research.

[21]  G. Peters,et al.  Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  Y. Yen,et al.  Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. , 1999, Cancer research.

[23]  G. Peters,et al.  The role of deoxycytidine kinase in gemcitabine cytotoxicity. , 2000, Advances in experimental medicine and biology.

[24]  J. Dagorn,et al.  p8 Is a New Target of Gemcitabine in Pancreatic Cancer Cells , 2006, Clinical Cancer Research.

[25]  A. Hajri,et al.  Telomerase transcriptional targeting of inducible Bax/TRAIL gene therapy improves gemcitabine treatment of pancreatic cancer. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  J. Mackey,et al.  Nucleoside analogues: mechanisms of drug resistance and reversal strategies , 2001, Leukemia.

[27]  G. Peters,et al.  Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine) , 2002 .

[28]  V. Heinemann,et al.  Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. , 1988, Cancer research.

[29]  R. Hruban,et al.  Epidemiology and risk factors , 2002 .

[30]  M. Mattson,et al.  Activation of NF‐κB protects hippocampal neurons against oxidative stress‐induced apoptosis: Evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration , 1997, Journal of neuroscience research.

[31]  V. Heinemann,et al.  Gemcitabine: metabolism, mechanisms of action, and self-potentiation. , 1995, Seminars in oncology.

[32]  G. Peters,et al.  2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. , 1993, Biochemical pharmacology.

[33]  L. Hertel,et al.  Action of 2',2'-difluorodeoxycytidine on DNA synthesis. , 1991, Cancer research.

[34]  J. Laliberté,et al.  Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. , 1993, Biochemical pharmacology.

[35]  David R. Jones,et al.  Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. , 2004, The Annals of thoracic surgery.

[36]  G. Peters,et al.  Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. , 1992, Cancer research.

[37]  J. Roth,et al.  A rapid and efficient method for purification of recombinant adenovirus with arginine-glycine-aspartic acid-modified fibers. , 2006, Analytical biochemistry.

[38]  Douglas B. Evans,et al.  The function of multiple IκB : NF-κB complexes in the resistance of cancer cells to Taxol-induced apoptosis , 2002, Oncogene.

[39]  S. Ashley,et al.  Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma Cells , 2004, Clinical Cancer Research.

[40]  J. Neijt,et al.  Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. , 1994, Journal of the National Cancer Institute.

[41]  H. Kalthoff,et al.  Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin , 2001, Oncogene.

[42]  S. Ashley,et al.  RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine , 2004, Oncogene.

[43]  C. Beauséjour,et al.  Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene. , 2002, Biochemical and biophysical research communications.

[44]  Douglas B. Evans,et al.  Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA , 1999, Oncogene.

[45]  P. Wen,et al.  Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo , 1996, Nature Medicine.

[46]  L. Pradayrol,et al.  Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[47]  F. Graham,et al.  Manipulation of adenovirus vectors. , 1991, Methods in molecular biology.

[48]  中野 靖弘,et al.  Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells , 2007 .

[49]  Bauke Ylstra,et al.  In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. , 2005, Cancer research.

[50]  W. Bezwoda,et al.  Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Volker Heinemann,et al.  Gemcitabine: Progress in the Treatment of Pancreatic Cancer , 2000, Oncology.

[52]  Douglas B. Evans,et al.  The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. , 2002, Oncogene.